A204840 Stock Overview
Provides generic drugs and incrementally modified drug (IMD) formulation technology to pharmaceutical companies in South Korea.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
GL Pharm Tech Corp. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | ₩1,151.00 |
| 52 Week High | ₩1,830.00 |
| 52 Week Low | ₩705.00 |
| Beta | 1.01 |
| 11 Month Change | 4.16% |
| 3 Month Change | -3.36% |
| 1 Year Change | 43.70% |
| 33 Year Change | -10.78% |
| 5 Year Change | -43.99% |
| Change since IPO | -83.29% |
Recent News & Updates
Recent updates
Is GL Pharm Tech (KOSDAQ:204840) A Risky Investment?
Jul 23
Market Participants Recognise GL Pharm Tech Corp.'s (KOSDAQ:204840) Revenues Pushing Shares 25% Higher
Mar 01Would GL Pharm Tech (KOSDAQ:204840) Be Better Off With Less Debt?
Mar 30The GL Pharm Tech (KOSDAQ:204840) Share Price Is Up 50% And Shareholders Are Holding On
Dec 15Shareholder Returns
| A204840 | KR Pharmaceuticals | KR Market | |
|---|---|---|---|
| 7D | 11.4% | -1.7% | -3.7% |
| 1Y | 43.7% | 14.6% | 2.4% |
Return vs Industry: A204840 exceeded the KR Pharmaceuticals industry which returned 14.6% over the past year.
Return vs Market: A204840 exceeded the KR Market which returned 2.4% over the past year.
Price Volatility
| A204840 volatility | |
|---|---|
| A204840 Average Weekly Movement | 5.6% |
| Pharmaceuticals Industry Average Movement | 3.8% |
| Market Average Movement | 5.0% |
| 10% most volatile stocks in KR Market | 11.1% |
| 10% least volatile stocks in KR Market | 2.2% |
Stable Share Price: A204840 has not had significant price volatility in the past 3 months.
Volatility Over Time: A204840's weekly volatility (6%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2002 | 22 | Hun-Sik Wang | www.glpt.co.kr |
GL Pharm Tech Corp. provides generic drugs and incrementally modified drug (IMD) formulation technology to pharmaceutical companies in South Korea. The company offers IMD for gastritis, antidepressant, anorectic, and antibiotic indications. It also provides generic drugs for cardiovascular, urology, pain, anti-infection, gastric disease, diabetes, central nervous system disease, respiratory disease, transplantation, and other areas.
GL Pharm Tech Corp. Fundamentals Summary
| A204840 fundamental statistics | |
|---|---|
| Market cap | ₩88.28b |
| Earnings (TTM) | -₩4.78b |
| Revenue (TTM) | ₩26.76b |
3.3x
P/S Ratio-18.5x
P/E RatioIs A204840 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| A204840 income statement (TTM) | |
|---|---|
| Revenue | ₩26.76b |
| Cost of Revenue | ₩18.33b |
| Gross Profit | ₩8.43b |
| Other Expenses | ₩13.21b |
| Earnings | -₩4.78b |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -62.36 |
| Gross Margin | 31.50% |
| Net Profit Margin | -17.87% |
| Debt/Equity Ratio | 81.8% |
How did A204840 perform over the long term?
See historical performance and comparison